OrbiMed’s Vanda Pharmaceuticals VNDA Stock Holding History

OrbiMed’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-139,400	Closed	-$1.53M	–	135
2013 Q3	$1.53M	Buy	+139,400	New	+$1.49M	0.03%	122

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

OrbiMed's VNDA Position: Q1 2018 in Review

OrbiMed sold out of Vanda Pharmaceuticals (VNDA) in Q1 2018, closing a stake of 967,859 shares — an estimated $14.7M sold.

OrbiMed first reported a position in VNDA in Q4 2013 and held it in 7 quarters. The position peaked at $17.3M in Q3 2017. 131 funds tracked by Wall St. Rank hold VNDA as of Q1 2018.

OrbiMed reported no remaining Vanda Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
OrbiMed sold 967,859 Vanda Pharmaceuticals shares in Q1 2018, an estimated $14.7M.
OrbiMed first reported a position in Vanda Pharmaceuticals in Q4 2013 and held it in 7 quarters.
OrbiMed's Vanda Pharmaceuticals position peaked at $17.3M in Q3 2017.
131 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2018.

Based on OrbiMed's 13F filing for Q1 2018, filed 15 May 2018.